Near-term
Platform
AI tools: digitised formulas, compound–target maps, docking and ADMET prediction.
For: Universities, CROs and research teams
Guide
A plain-language guide to finding drug leads in natural products and traditional medicine, and how BBCRI applies these methods in Bhutan.
Many of the medicines in use today began as natural products. Aspirin traces back to compounds in willow bark. The cancer drug paclitaxel was first isolated from the bark of the Pacific yew. Artemisinin, now a standard treatment for malaria, was isolated from sweet wormwood, a plant recorded in traditional Chinese medicine; that work was recognised with a Nobel Prize in 2015.
Traditional medical systems hold a long record of which plants people have used, for what, and in which combinations. That record does not prove a remedy works. It does suggest where to look first.
Three things have made this work more practical. Omics technologies can profile the genes, proteins and metabolites of a plant in detail. Public databases now hold large numbers of known compounds and biological targets. And computing power and machine learning make it possible to search across all of that quickly.
Computational methods produce predictions, not proof. They depend on the quality of the data behind them, and most candidates that look promising on a computer do not survive laboratory testing. A compound that does pass still faces years of preclinical and clinical study before it could become a medicine. AI makes the search faster and better aimed. It does not remove the need to test.
BBCRI is building Sowa-Omics™, a research platform that applies these methods to Sowa Rigpa, the traditional medicine of Bhutan, and to Bhutanese medicinal plants. The platform is designed to work in stages:
We are at the prototype stage. See our research pipeline for where each programme really stands, and our guide to Sowa Rigpa for the tradition behind it.
Near-term
AI tools: digitised formulas, compound–target maps, docking and ADMET prediction.
For: Universities, CROs and research teams
Near-term
Contract work in network pharmacology and in-silico screening, built on the same platform.
For: Institutions, agencies and companies
Long-term
Co-develop natural-product leads with industry partners through research fees, milestone payments and royalties.
For: Pharma and nutraceutical companies
If you work in natural products, computational biology or drug development, see how to partner with BBCRI.
It is the use of machine learning and other computational methods to help find and prioritise possible medicines: predicting which compounds might act on a biological target, and which are likely to be absorbed and tolerated, before they are tested in a laboratory.
It is a way of studying how several compounds act on several biological targets at once, by mapping them as a network. It suits traditional formulas, which combine many ingredients on purpose.
No. BBCRI is an early-stage company with a working software prototype. It has not yet produced a laboratory-validated lead. Nothing is called a therapy until it has been validated.
This page is general information about research methods. It is not medical advice.
Investors, partners and customers: tell us what you have in mind. We reply to every message.